Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12 (5), 461-75

The Role of Noradrenaline and Selective Noradrenaline Reuptake Inhibition in Depression


The Role of Noradrenaline and Selective Noradrenaline Reuptake Inhibition in Depression

N Brunello et al. Eur Neuropsychopharmacol.


Depression is a common disorder that impacts on all aspects of a person's life. For the past 10 years, clinicians have focused on serotonin in their treatment of depression. This is largely due to the growing acceptance of the efficacy and safety of the selective serotonin reuptake inhibitors (SSRIs) in comparison with older tricyclic antidepressants (TCAs). However, evidence for a role of noradrenaline in depression has been accumulating for some time, beginning with the discovery that drugs which either caused or alleviated depression acted to alter noradrenaline metabolism. Until recently, the role of noradrenaline in depression was predicted from clinical experience with noradrenergic TCAs (desipramine, nortriptyline and protriptyline) and selective serotonin and noradrenaline reuptake inhibitors (venlafaxine, milnacipran). The licensing of reboxetine, a selective noradrenaline reuptake inhibitor now allows the role of noradrenaline in depression to be investigated directly. This review presents key data from the literature that support a role for noradrenaline in depression taking into account neurophysiology, psychopharmacology and clinical trial data.

Similar articles

  • Is There a Role for a Pure Noradrenergic Drug in the Treatment of Depression?
    SA Montgomery. Eur Neuropsychopharmacol 7 Suppl 1, S3-9; discussion S71-3. PMID 9169305. - Review
    Depression is thought to result from a dysfunction in the noradrenergic or serotonergic systems. The noradrenergic system appears to be associated with increased drive, w …
  • Predicting Response: Noradrenaline Reuptake Inhibition
    SA Montgomery. Int Clin Psychopharmacol 14 Suppl 1, S21-6. PMID 10468325. - Review
    For the past decade, the role of noradrenaline in depression has been somewhat neglected in favour of serotonin. This is largely because of the advent of the selective se …
  • The Need for New and Better Antidepressants: Reboxetine a New Option
    SJ Dencker. Acta Psychiatr Scand Suppl 402, 6-11. PMID 10901153. - Review
    The selective serotonin reuptake inhibitors (SSRIs) have obtained global attention but have not demonstrated superior efficacy in major depression compared with older tri …
  • Noradrenaline in Basic Models of Depression
    BE Leonard. Eur Neuropsychopharmacol 7 Suppl 1, S11-6; discussion S71-3. PMID 9169306. - Review
    This review reports anatomical studies evaluating central and peripheral alpha 2- and beta-adrenoceptors. The results suggest abnormalities exist in the noradrenergic sys …
  • Clinical Efficacy of Reboxetine in Major Depression
    AF Schatzberg. J Clin Psychiatry 61 Suppl 10, 31-8. PMID 10910015. - Review
    The past decade has witnessed the advent of selective serotonin reuptake inhibitors (SSRIs) as first-line treatments for major depression. Still, there is considerable de …
See all similar articles

Cited by 27 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources